Financial Data and Key Metrics Changes - Total revenue for 2023 was $170.3 million, an 8% decrease year-over-year [16] - Q4 revenue was $45.8 million, with 67% from MRD and 33% from Immune Medicine [15] - MRD revenue for the full year was $102.7 million, up 18% from the previous year, while Immune Medicine revenue was $67.5 million, down 31% [16] - Gross margin for Q4 was 57%, an 8-point increase from Q3 but a 13-point decline year-over-year [17] - Net loss for the full year was $225.3 million, compared to $200.4 million in 2022 [18] Business Line Data and Key Metrics Changes - MRD business grew 27% year-over-year excluding milestones, driven by clonoSEQ volume growth [5][6] - clonoSEQ clinical revenue in Q4 grew 56% year-over-year, with test volumes increasing by 49% [7][8] - Immune Medicine revenue decreased by 45% year-over-year, primarily due to lower Genentech amortization [16] Market Data and Key Metrics Changes - The MRD business is expected to contribute between $130 million and $140 million in revenue for 2024, with a conservative growth outlook for Pharma services [19] - The company anticipates a 45% to 55% revenue split between the first and second halves of 2024 [20] Company Strategy and Development Direction - The company is focusing on a strategic review to maximize shareholder value, with plans to communicate outcomes by the end of the current quarter [7] - The MRD business aims to reach profitability by the end of 2025, while the Immune Medicine segment will focus on targeted drug discovery [6][12] - The company is enhancing its customer experience through EMR integrations and partnerships, including a new agreement with Flatiron Health [10][13] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of the clonoSEQ MRD business and the potential of the Immune Medicine pipeline [22] - The company is optimistic about the impact of state biomarker laws on business, although these benefits are not included in the 2024 guidance [80] Other Important Information - The company ended 2023 with approximately $346 million in cash equivalents, allowing for strategic investments [18] - The company is implementing operational efficiencies to reduce burn rate to an average of $35 million per quarter in 2024 [20] Q&A Session Summary Question: Can you walk through the OpEx outlook for '24 and the revenue considerations for burn? - Management indicated a burn rate of $35 million per quarter, emphasizing ongoing efficiency drives across the organization [24] Question: What are the expectations for MRD revenue cadence in the year? - Management noted that Q4 typically has fewer business days, impacting growth rates, but leading indicators remain positive [32] Question: Can you elaborate on the strategic review outcome expected at the end of the quarter? - Management refrained from commenting on specific structures but emphasized a strong cash position and commitment to maximizing stakeholder value [29] Question: What are the trends in the MRD Pharma side, specifically regarding cancellations or delays? - Management noted a decline in the number of trials in multiple myeloma, impacting growth opportunities, while non-Hodgkins lymphoma remains stable [66] Question: Can you provide details on the partnership with Flatiron Health? - The partnership involves a setup fee and an annual fee, with no milestone payments specified [74] Question: How is the Epic integration performing? - Feedback has been positive, with increased volumes and reduced manpower for order entry noted [75]

Fourth Quarter and FY 2023 Earnings Conference Call Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation ...

SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 9th at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Nitin Sood - Chief Commercial Officer, MRD Susan Bobulsky - Senior Vice President, Diagnostics, clonoSEQ Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Mark Massaro - BTIG Dan Brennan - TD Cowen David Westenberg - Piper Sandler Operator Thank you for stan ...

Third Quarter 2023 Earnings Conference Call Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-09 ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2023 Results Conference Call August 2, 2023 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Nitin Sood - Chief Commercial Officer, MRD Harlan Robins - Chief Scientific Officer and Co-founder Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Rachel Vatnsdal - JPMorgan Chase Dan Brennan - TD Cowen David Westenberg - Piper Sandler Mark Massaro - BTIG Eli ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Co-founder, Chairman & Chief Executive Officer Tycho Peterson - Chief Financial Officer Nitin Sood - Chief Commercial Officer, MRD Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Derik De Bruin - Bank of America Yuko Oku ...

Financial Performance - Revenue for Q1 2023 was $37,647,000, a decrease of 2.5% compared to $38,620,000 in Q1 2022[10] - Total operating expenses for Q1 2023 were $94,840,000, down from $101,687,000 in Q1 2022, representing a reduction of approximately 6.7%[10] - Net loss for Q1 2023 was $57,700,000, compared to a net loss of $62,796,000 in Q1 2022, indicating an improvement of about 8.4%[10] - The company reported a comprehensive loss of $55,489,000 for Q1 2023, an improvement from a comprehensive loss of $66,442,000 in Q1 2022[12] - Net loss for the three months ended March 31, 2023, was $57.7 million, an improvement from a net loss of $62.8 million for the same period in 2022, representing a decrease of approximately 3.5%[16] - The net loss attributable to the company for the three months ended March 31, 2023, was $57.699 million, compared to a net loss of $62.736 million for the same period in 2022, indicating a reduction in loss of approximately 8%[76] - Adjusted EBITDA for the three months ended March 31, 2023, was $(37,098,000), an improvement from $(43,078,000) in the same period of 2022[102] Cash and Assets - Cash and cash equivalents increased to $94,612,000 as of March 31, 2023, up from $90,030,000 at the end of 2022[8] - Total assets decreased to $791,463,000 as of March 31, 2023, down from $856,617,000 at the end of 2022, reflecting a decline of approximately 7.6%[8] - Cash, cash equivalents, and restricted cash at the end of the period were $96.9 million, down from $117.2 million at the end of March 31, 2022, indicating a decrease of approximately 17.3%[16] - As of March 31, 2023, the company had cash, cash equivalents, and marketable securities totaling $440.7 million, down from $498.2 million as of December 31, 2022[80] Revenue Breakdown - Revenue from significant customers included Genentech, Inc. and Roche Group, contributing 26.6% of total revenue for the three months ended March 31, 2023, compared to 33.8% in the same period of 2022[25] - Immune Medicine revenue for Q1 2023 was $16.220 million, down 22.8% from $20.816 million in Q1 2022[29] - MRD service revenue increased significantly to $21.427 million in Q1 2023, compared to $14.804 million in Q1 2022, representing a growth of 44.7%[29] - The company recognized $9.1 million in collaboration revenue from the Genentech Agreement in Q1 2023, down from $12.3 million in Q1 2022[33] - Immune Medicine revenue decreased by $4,596,000, or 22%, primarily due to a $3,200,000 decrease from the Genentech Agreement and a $1,000,000 decrease from biopharmaceutical customers[93] - MRD revenue increased by $3,623,000, or 20%, driven by a $4,000,000 increase from clonoSEQ services and a $1,500,000 increase from MRD sample testing services[93] Expenses - Research and development expenses for Q1 2023 were $32,601,000, down from $37,839,000 in Q1 2022, a decrease of approximately 13.8%[10] - Research and development expenses decreased by $5,238,000, or 14%, mainly due to reduced investments in T-Detect and TCRAntigen Map development[95] - Sales and marketing expenses decreased by $3,785,000, or 15%, primarily due to lower personnel and marketing costs[98] - General and administrative expenses decreased by $3,313,000, or 14%, largely due to reduced building and facility-related expenses[99] - The company’s share-based compensation expense increased to $14.7 million for the three months ended March 31, 2023, compared to $12.9 million for the same period in 2022, reflecting an increase of approximately 14%[16] Future Outlook - The company expects revenue to increase over the long term, although fluctuations may occur due to the uncertain nature of product delivery and customer decisions[81] - The company expects revenue from current and future products and services to grow over the long term, despite potential near-term variability[104] - The company plans to utilize existing cash primarily for research and development initiatives, marketing activities, and streamlining laboratory operations[104] - The company is focused on expanding revenue in two growth areas: IM Pharma Services and Drug Discovery, leveraging its proprietary technologies[80] Liabilities and Agreements - Current liabilities decreased to $90,101,000 as of March 31, 2023, compared to $109,788,000 at the end of 2022, a reduction of about 18%[8] - The revenue interest liability increased from $125.360 million at December 31, 2022, to $127.008 million by March 31, 2023, with interest expense of $3.531 million recorded[49] - The company has a collaboration agreement with Genentech, which is a significant component of its revenue generation strategy[81] - The company has a responsibility to enter into a supply and manufacturing agreement for patient-specific TCRs related to Personalized Product therapies, which is contingent on Genentech's commercialization decisions[32] Stock and Equity - As of March 31, 2023, the company had reserved a total of 44,794,592 shares of common stock for future issuance under various equity incentive plans[54] - The company had 14,783,332 stock options outstanding with a weighted average exercise price of $15.97[61] - The total share-based compensation expense for the three months ended March 31, 2023, was $14.671 million, compared to $12.861 million for the same period in 2022, representing an increase of approximately 14%[71] - The weighted-average grant date fair value per share of stock options granted during the three months ended March 31, 2023, was $5.61, down from $7.81 in 2022[70] - The company granted 6,486,163 restricted stock units during the three months ended March 31, 2023, with 1,029,209 units vested during the same period[63]